{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T04:48:14Z","timestamp":1764305294933},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1097\/mbc.0000000000000018","type":"journal-article","created":{"date-parts":[[2013,11,14]],"date-time":"2013-11-14T08:46:43Z","timestamp":1384418803000},"page":"384-386","source":"Crossref","is-referenced-by-count":3,"title":["Life-threatening epistaxis and red blood cell polyagglutination under dabigatran"],"prefix":"10.1097","volume":"25","author":[{"given":"Claudia","family":"St\u00f6llberger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Krutisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef","family":"Finsterer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-17-20210203","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation.","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"R2-17-20210203","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1161\/CIRCULATIONAHA.111.031153","article-title":"Should newer oral anticoagulants be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation.","volume":"125","author":"Ansell","year":"2012","journal-title":"Circulation"},{"key":"R3-17-20210203","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1160\/TH13-03-0246","article-title":"Contra: new oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation.","volume":"110","author":"Stollberger","year":"2013","journal-title":"Thromb Haemost"},{"key":"R5-17-20210203","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.2215\/CJN.01570213","article-title":"Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience.","volume":"8","author":"Singh","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"R6-17-20210203","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3109\/15563650.2012.721888","article-title":"Hemorrhagic complications associated with dabigatran use.","volume":"50","author":"Chen","year":"2012","journal-title":"Clin Toxicol (Phila)"},{"key":"R7-17-20210203","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.2146\/ajhp110644","article-title":"Epistaxis associated with dabigatran in an elderly patient with reduced creatinine clearance.","volume":"69","author":"Freshour","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"R8-17-20210203","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1001\/archinternmed.2011.314","article-title":"The use of dabigatran in elderly patients.","volume":"171","author":"Legrand","year":"2011","journal-title":"Arch Intern Med"},{"key":"R10-17-20210203","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.amjcard.2012.12.045","article-title":"Renal impairment in a real-life cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding).","volume":"111","author":"Roldan","year":"2013","journal-title":"Am J Cardiol"},{"key":"R11-17-20210203","first-page":"13","article-title":"Does vasopressor therapy have an indication in hemorrhagic shock Ann Intensive C","volume":"3","author":"Beloncle","year":"2013","journal-title":"are"},{"key":"R12-17-20210203","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0037-1963(00)90043-X","article-title":"Red blood cell polyagglutination: clinical aspects.","volume":"37","author":"Beck","year":"2000","journal-title":"Semin Hematol"},{"key":"R13-17-20210203","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1021\/jm3001339","article-title":"Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).","volume":"55","author":"Michaelis","year":"2012","journal-title":"J Med Chem"},{"key":"R14-17-20210203","doi-asserted-by":"crossref","first-page":"30917","DOI":"10.1074\/jbc.M605809200","article-title":"NQO1 and NQO2 regulation of humoral immunity and autoimmunity.","volume":"281","author":"Iskander","year":"2006","journal-title":"J Biol Chem"}],"container-title":["Blood Coagulation & Fibrinolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MBC.0000000000000018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:21:11Z","timestamp":1620958871000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001721-201406000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/mbc.0000000000000018","relation":{},"ISSN":["0957-5235"],"issn-type":[{"value":"0957-5235","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}